Before you sell to, join or invest in ImmuneBridge Inc.
MentionFox check on ImmuneBridge Inc.: only 1 source on file so far (checked 4 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/immunebridge-inc-form-d-25000001
Check ImmuneBridge Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about ImmuneBridge Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
ImmuneBridge Inc. filed a Form D with the Securities and Exchange Commission on 2025-04-02.
ImmuneBridge Inc. filed a Form D notice of an exempt securities offering with the SEC on April 2, 2025. The filing reports $5.63M sold. Its industry group is Biotechnology. It names Stuart Jacobson (Executive Officer, Director), Dylan Morris (Director), Nadiya Ishnazarova (Director) (SEC Form D, April 2, 2025).
Is this your company?
Sell to companies like ImmuneBridge Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-04-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ImmuneBridge Inc.
Free to see. No signup.
More on the people and the money behind ImmuneBridge Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in April 2025, largest first.
Get an email when ImmuneBridge Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ImmuneBridge Inc. raises, hires or launches. No email unless you switch it on.
Watch ImmuneBridge Inc. →Get the full cited report on ImmuneBridge Inc.
What the filing shows about ImmuneBridge Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ImmuneBridge Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives ImmuneBridge Inc.'s address as 2122 Bryant St, San Francisco, CA 94110.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
ImmuneBridge Inc. is a registered filer with the SEC (CIK 1960306) and has filed since 2023-01-10. 2 filings are on record, the latest on 2025-04-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
ImmuneBridge Inc.'s Form D of 2025-04-02 names Stuart Jacobson, Dylan Morris, Nadiya Ishnazarova and 3 more as its officers, directors or promoters.
Its new offerings report $15.78M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Stuart Jacobson is named as Executive Officer and Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
Dylan Morris is named as Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
Nadiya Ishnazarova is named as Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
Omri Amirav-Drory is named as Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
Thomas Farrell is named as Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
Alicia Jackson is named as Director on the Form D that ImmuneBridge Inc. filed with the SEC on 2 April 2025, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2025-04-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ImmuneBridge Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ImmuneBridge Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ImmuneBridge Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ImmuneBridge Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind ImmuneBridge Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ImmuneBridge Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Francisco Bay Area
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/immunebridge-inc-form-d-25000001